Nanoparticle-mediated delivery of PD-L1 inhibitor enhances γδ T cell immunotherapy against metastatic ovarian cancer cells
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Immune checkpoint inhibitors (ICIs) have only shown limited efficacy for patients with ovarian cancer (OC), partly due to the immune suppressive tumour microenvironment (TME) and platelet cloaking of the cancer cells. We tested a nanomedicine strategy to enhance γδ T cell immunotherapy by conjugating the PD-L1 inhibitor (BMS202) to nanodiamonds (NDs).
Methods
Patient-derived ascites cells were exposed to activated platelets to model platelet cloaking and the immunosuppressive phenotype in metastatic OC. ND/BMS202 nanocomplexes were then applied to platelet-conditioned OC cells and co-cultured with expanded γδ T cells. Cytotoxicity and immune activation were assessed by quantifying Granzyme B, CD107a, γ-H2AX, cleaved caspase-3, and cleaved caspase-8.
Results
ND-mediated delivery of BMS202 significantly enhanced γδ T cell-mediated killing of platelet cloaked OC cells in a dose-dependent manner, with greater efficacy than free BMS202 This enhanced cytotoxicity was supported by increased degranulation (CD107a), Granzyme B release, tumour cell apoptosis (caspase cleavage) and DNA damage (γ-H2AX staining).
Conclusions
ND-based delivery of the PD-L1 inhibitor (BMS202) enhances γδ T cell-mediated killing of platelet-cloaked metastatic OC cells. While our data support enhanced γδ T cell cytotoxicity following BMS202 delivery, direct evidence of PD-L1 target engagement or PD-1/PD-L1 binding inhibition was not demonstrated in this study. These findings nonetheless justify further validation in patient-derived organoid models to optimize this γδ T cell-based combination immunotherapy and advance its development as a precision therapeutic strategy for metastatic OC.
